MX2014007895A - Inhibidores de iap. - Google Patents

Inhibidores de iap.

Info

Publication number
MX2014007895A
MX2014007895A MX2014007895A MX2014007895A MX2014007895A MX 2014007895 A MX2014007895 A MX 2014007895A MX 2014007895 A MX2014007895 A MX 2014007895A MX 2014007895 A MX2014007895 A MX 2014007895A MX 2014007895 A MX2014007895 A MX 2014007895A
Authority
MX
Mexico
Prior art keywords
iap
inhibitors
useful
general formula
therapeutic agents
Prior art date
Application number
MX2014007895A
Other languages
English (en)
Other versions
MX336294B (es
Inventor
Vickie Hsiao-Wei Tsui
Frederick Cohen
Lewis J Gazzard
John A Flygare
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of MX2014007895A publication Critical patent/MX2014007895A/es
Publication of MX336294B publication Critical patent/MX336294B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/4211,3-Oxazoles, e.g. pemoline, trimethadione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0812Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0815Tripeptides with the first amino acid being basic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Inhibidores de IAP novedosos que son útiles como agentes terapéuticos para el tratamiento de tumores malignos y que tienen la fórmula general (I): en donde R1, R2, R3, R4, R5 y R6 son como se describen en la presente. (ver Fórmula).
MX2014007895A 2012-01-03 2013-01-03 Inhibidores de iap. MX336294B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261582760P 2012-01-03 2012-01-03
PCT/US2013/020124 WO2013103703A1 (en) 2012-01-03 2013-01-03 Inhibitors of iap

Publications (2)

Publication Number Publication Date
MX2014007895A true MX2014007895A (es) 2015-03-19
MX336294B MX336294B (es) 2016-01-14

Family

ID=48695302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007895A MX336294B (es) 2012-01-03 2013-01-03 Inhibidores de iap.

Country Status (41)

Country Link
US (6) US8716236B2 (es)
EP (2) EP2800749B1 (es)
JP (2) JP5747137B2 (es)
KR (3) KR101855566B1 (es)
CN (2) CN104159897A (es)
AR (2) AR089623A1 (es)
AU (1) AU2013202780B2 (es)
BR (1) BR112014016637B1 (es)
CA (1) CA2861637C (es)
CL (1) CL2014001770A1 (es)
CO (1) CO7020915A2 (es)
CR (1) CR20140367A (es)
CY (2) CY1118371T1 (es)
DK (2) DK3133073T3 (es)
EC (1) ECSP14011792A (es)
ES (2) ES2672809T3 (es)
HK (1) HK1203949A1 (es)
HR (2) HRP20161381T1 (es)
HU (2) HUE031305T2 (es)
IL (2) IL242314A (es)
LT (2) LT2800749T (es)
MA (1) MA35895B1 (es)
ME (2) ME02526B (es)
MX (1) MX336294B (es)
MY (1) MY178390A (es)
NO (1) NO2755614T3 (es)
NZ (1) NZ627480A (es)
PE (1) PE20142182A1 (es)
PH (2) PH12014501534B1 (es)
PL (2) PL2800749T3 (es)
PT (2) PT2800749T (es)
RS (2) RS55327B1 (es)
RU (2) RU2593259C2 (es)
SG (1) SG11201403784QA (es)
SI (2) SI2800749T1 (es)
SM (1) SMT201600357B (es)
TR (1) TR201808088T4 (es)
TW (1) TWI503318B (es)
UA (1) UA114417C2 (es)
WO (1) WO2013103703A1 (es)
ZA (1) ZA201405535B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2755614T3 (es) * 2012-01-03 2018-03-31
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
CN109705191B (zh) * 2017-10-25 2022-04-29 广东东阳光药业有限公司 Iap抑制剂及其在药物中的应用
WO2019091492A1 (zh) 2017-11-13 2019-05-16 南京明德新药研发股份有限公司 用作iap抑制剂的smac模拟物及其用途
JPWO2020027225A1 (ja) 2018-07-31 2021-11-11 ファイメクス株式会社 複素環化合物
JPWO2021020585A1 (es) 2019-07-31 2021-02-04
MX2022008874A (es) 2020-01-20 2022-08-11 Astrazeneca Ab Inhibidores de la tirosina cinasa del receptor del factor de creciminto epidermico para el tratamiento del cancer.
WO2023239422A2 (en) 2021-10-22 2023-12-14 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
ATE297904T1 (de) 1997-04-15 2005-07-15 Genentech Inc Halo-alkoxycarbonylverbindungen
RS53734B1 (en) * 2004-07-02 2015-06-30 Genentech Inc. IAP INHIBITORS
NZ589670A (en) * 2004-12-20 2013-01-25 Genentech Inc Pyrrolidine inhibitors of iap
BRPI0719221A2 (pt) * 2006-10-12 2014-03-18 Novartis Ag Derivados de pirrolidina como inibidores de iap
MX2009011783A (es) * 2007-04-30 2009-12-04 Genentech Inc Inhibidores de iap.
NO2755614T3 (es) 2012-01-03 2018-03-31
USD690416S1 (en) 2012-12-12 2013-09-24 Pharmajet, Inc. Needle-free syringe

Also Published As

Publication number Publication date
HUE031305T2 (hu) 2017-07-28
US9238675B2 (en) 2016-01-19
SI2800749T1 (sl) 2016-11-30
KR101855566B1 (ko) 2018-05-04
US20220211797A1 (en) 2022-07-07
US9586991B2 (en) 2017-03-07
US20190224269A1 (en) 2019-07-25
RU2014130171A (ru) 2016-02-27
EP2800749A1 (en) 2014-11-12
AR123542A2 (es) 2022-12-14
SI3133073T1 (en) 2018-06-29
US20160102119A1 (en) 2016-04-14
IL242314A (en) 2016-08-31
US20140235551A1 (en) 2014-08-21
BR112014016637B1 (pt) 2022-06-14
CO7020915A2 (es) 2014-08-11
RU2593259C2 (ru) 2016-08-10
RU2016124658A3 (es) 2019-09-09
ECSP14011792A (es) 2015-12-31
SG11201403784QA (en) 2014-08-28
NZ627480A (en) 2016-04-29
DK2800749T3 (en) 2016-11-07
US20130172264A1 (en) 2013-07-04
WO2013103703A1 (en) 2013-07-11
US11963994B2 (en) 2024-04-23
US20170136084A1 (en) 2017-05-18
CN107915728B (zh) 2021-04-30
US11096982B2 (en) 2021-08-24
AU2013202780B2 (en) 2015-04-16
CL2014001770A1 (es) 2015-04-17
IL233386A (en) 2016-08-31
AR089623A1 (es) 2014-09-03
PH12015501038B1 (en) 2015-09-21
KR20180051646A (ko) 2018-05-16
EP3133073A2 (en) 2017-02-22
CR20140367A (es) 2015-02-18
ME03084B (me) 2019-01-20
HRP20180976T1 (hr) 2018-08-10
ES2672809T3 (es) 2018-06-18
PH12014501534A1 (en) 2014-10-08
AU2013202780A1 (en) 2013-07-18
SMT201600357B (it) 2016-11-10
MX336294B (es) 2016-01-14
DK3133073T3 (en) 2018-06-18
CY1118371T1 (el) 2017-06-28
CY1120355T1 (el) 2019-07-10
RU2016124658A (ru) 2018-12-04
MY178390A (en) 2020-10-12
PL3133073T3 (pl) 2018-09-28
JP5747137B2 (ja) 2015-07-08
PT3133073T (pt) 2018-06-18
PL2800749T3 (pl) 2017-01-31
TR201808088T4 (tr) 2018-06-21
PH12015501038A1 (en) 2015-09-21
RS55327B1 (sr) 2017-03-31
LT3133073T (lt) 2018-06-25
EP2800749B1 (en) 2016-09-21
KR101917992B1 (ko) 2018-11-13
KR20140107670A (ko) 2014-09-04
UA114417C2 (uk) 2017-06-12
PE20142182A1 (es) 2015-01-16
IL233386A0 (en) 2014-08-31
ZA201405535B (en) 2017-08-30
HRP20161381T1 (hr) 2016-12-02
CA2861637C (en) 2017-07-18
EP3133073B1 (en) 2018-05-02
RU2728789C2 (ru) 2020-07-31
CN104159897A (zh) 2014-11-19
ME02526B (me) 2017-02-20
HK1203949A1 (en) 2015-11-06
EP2800749A4 (en) 2015-08-05
JP2015504072A (ja) 2015-02-05
US8716236B2 (en) 2014-05-06
CA2861637A1 (en) 2013-07-11
EP3133073A3 (en) 2017-03-22
KR101553792B1 (ko) 2015-09-16
RS57438B1 (sr) 2018-09-28
PT2800749T (pt) 2016-10-24
TWI503318B (zh) 2015-10-11
JP2015199738A (ja) 2015-11-12
BR112014016637A2 (pt) 2017-06-13
KR20150065960A (ko) 2015-06-15
HUE037760T2 (hu) 2018-09-28
PH12014501534B1 (en) 2014-10-08
TW201333001A (zh) 2013-08-16
LT2800749T (lt) 2016-10-25
CN107915728A (zh) 2018-04-17
BR112014016637A8 (pt) 2017-07-04
ES2594856T3 (es) 2016-12-23
MA35895B1 (fr) 2014-12-01
NO2755614T3 (es) 2018-03-31

Similar Documents

Publication Publication Date Title
PH12017502141A1 (en) Compounds and their methods of use
IN2015DN01156A (es)
PH12015501038A1 (en) Inhibitors of iap
PH12014502573A1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
MY176680A (en) Cyclic amides as metap-2 inhibitors
MX356368B (es) Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
PH12014501365A1 (en) Compounds
MX2016006432A (es) Tetrahidro-benzodiazepinonas.
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2015001720A (es) Hetero-azepinonas sustituidas.
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
MX2013008212A (es) Derivados de 7-azaindol.
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
MX2014002208A (es) Inhibidores de serina/treonina quinasa.
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
PH12015501088A1 (en) Dimeric compounds
MX2014014832A (es) Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
GB201209587D0 (en) Therapeutic compounds
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
PH12015500399A1 (en) Azaindolines
MX365192B (es) Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
UA109932C2 (xx) Циклопропіламіни як інгібітори lsd1